Last reviewed · How we verify
Sanjin tablets
Sanjin tablets, developed by the China Academy of Chinese Medical Sciences, are a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Sanjin tablets |
|---|---|
| Also known as | levofloxacin simulants |
| Sponsor | China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |